Part II Supply: Strategy of Firms. Chapter 5 Innovation: Evolution and Motivation by Xiang Anbo & Chen Xianhong
Part II Supply: Strategy of Firms. Chapter 5
Innovation: Evolution and Motivation
権利 Copyrights 日本貿易振興機構（ジェトロ）アジア
経済研究所 / Institute of Developing
Economies, Japan External Trade Organization
(IDE-JETRO) http://www.ide.go.jp
シリーズタイトル(英
)
ASEDP 
シリーズ番号 75
journal or
publication title
Pharmaceutical Industry in China-Intellectual
Property Protection, Pricing and Innovation-
page range [89]-111
year 2007
URL http://hdl.handle.net/2344/00015893
Chapter 5 
 
Innovation: 
Evolution and Motivation 
 
Firms depend on innovation for survival, development and excellence, especially in the 
increasingly competitive and rapidly changing market environment. This chapter 
focuses on introducing and then analyzing the current status, evolution processes, 
experiences, and issues of innovation in the Chinese pharmaceutical industry. We try to 
reveal the motivation behind the efforts being made in this field, and to help understand 
how Chinese pharmaceutical provision can be sufficient and sustainable. 
 
 
5.1 Literature Review 
 
First of all, we must distinguish the differences between Invention” and Innovation. 
According to J. A. Schumpeter’s Innovation Theory, enterprise innovation is the 
introduction of a new combination (which consists of essential production factors and 
production conditions, and has never appeared before) into the production system, i.e. a 
new business success. Business innovation needs to go through a more complicated 
process and has many influencing factors (including a firm’s interior factors and 
external environmental factors), requires the capability to cover the whole value chain 
and various areas of knowledge (science, technology, manufacturing, and the market). 
Invention focuses on creating knowledge, i.e. it is a scientific activity, while innovation 
is an economical activity which emphasizes the commercialization of scientific 
production. 
 
Secondly, we must clarify the relationship between Innovation and R&D. There are five 
major patterns of innovation: product innovation (inventing new products), technology 
innovation (finding or improving new approaches in manufacturing), market innovation 
(developing new markets), resource allocation innovation (exploiting new supplies of 
resources), and organization innovation (utilizing new a organizational structure). All of 
these innovation patterns can be found in the Chinese pharmaceutical industry. In this 
section, we will focus on the first two, i.e. product and technology innovation, which 
also have reference to R&D. We should be aware that (1) innovation goes beyond R&D; 
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and (2) on the other hand, generic drugs are still the overwhelming majority of products 
in the Chinese pharmaceutical industry, and so some R&D resources are spent on the 
study of generic drugs. Therefore, R&D does not definitely mean or lead to innovation. 
 
There are several mechanisms to promote innovation: patents, sales margins, research 
and development subsidies, bonuses for new inventions, contract research and 
development, and research and development by public institutions (J. Lanjow, Lecture 
in 2005). Researchers often point out that patent protection is effective at raising the 
profits from, and investment into, research and development among pharmaceutical 
firms. Okada (2006) conducted an empirical test, which showed that for a patent that is 
frequently referred to in a different patent’s application, the subsequent sales of drug 
firms holding that patent increased by 30%. On the other hand, innovation heavily relies 
on human capital. It is difficult for managers, who do not directly engage in innovation, 
to control the innovation process. Thus the structure of governance is another noticeable, 
important and significant factor that affects firms’ innovative activities. These two 
points are discussed in detail in separate chapters, however, and so we will only briefly 
introduce them as and when necessary. 
 
 
5.2 Innovation in the Chinese Pharmaceutical Industry: a Survey 
 
The pharmaceutical industry is closely related to civil health, society stability, and 
economic development. It is an economic colony that merges multiple disciplines with 
advanced technology and techniques, and requires and calls on innovation out loud. 
R&D is the most pivotal competence in the competition for pharmaceutical firms to 
survive and succeed. Moreover, as we see later, the pharmaceutical industry’s technical 
innovation is a game characterized by huge investments, high risks, and a long time 
period. 
 
5.2.1 Basic Information on R&D in the Chinese Pharmaceutical Industry 
Generally speaking, low investment in R&D and lack of capability for innovation are 
two key factors that severely and directly restrict the Chinese pharmaceutical industry’s 
development and advancement. The average ratio of investment in R&D to revenue is 
about 1.5% in the Chinese pharmaceutical industry, which is much lower than the 
average level among international advanced pharmaceutical giants. Tables 1-6 outline 
the overall status of innovation in the Chinese pharmaceutical industry. 
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Table 1: Distribution of Independent-Innovation Enterprises in the Chinese 
Pharmaceutical Industry (2005) 
 
Industry 
# of Enterprises with 
Independent-Innovation Activities
(%) 
Raw Chemical Materials 
and Chemical Products 540 32.3 
Medical and Pharmaceutical 
Products 423 55.1 
 (Source) NBSC 
 
Table 2: R&D Personnel and Investment in the Chinese Pharmaceutical 
Industry (2005) 
 
Industry # of R&D Staff R&D Investment  
(RMB 10,000) 
Raw Chemical Materials and 
Chemical Products 46,334 846,315 
Medical and Pharmaceutical 
Products 23,949 399,510 
(Source) NBSC 
 
Table 3:  R&D Projects in the Chinese Pharmaceutical Industry (2005) 
 
Industry # of R&D  
Projects 
# of R&D 
Project Staff 
R&D  
Project  Fund 
(RMB 10,000) 
Raw Chemical Materials and 
Chemical Products 2,592 33,798 695,047 
Medical and Pharmaceutical 
Products 2,546 17,401 325,519 
(Source) NBSC 
 
 
Table 4:  Manufacturing and Sale of New Products in the Chinese 
Pharmaceutical Industry (2005) [RMB 100,000,000] 
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Industry New Products’ Value Sale of New Products
# Exported 
Raw Chemical Materials and 
Chemical Products 
1,044 1,039 146 
Medical and Pharmaceutical 
Products 512 469 71 
 (Source) NBSC 
 
 
Table 5:  Patent Application and Possession in the Chinese Pharmaceutical 
Industry (2005) 
 
 
Industry 
# of Patent 
Applications 
# of Invention 
Patents 
# of Invention Patents
Owned 
Raw Chemical Materials and 
Chemical Products 2,155 903 1,495 
Medical and Pharmaceutical 
Products 2,708 1,659 1,134 
(Source) NBSC 
 
Table 6:  Technology Acquisition (2005) [RMB 10,000] 
 
Industry 
Expenditure on 
Introduction of Overseas 
Technology 
Expenditure on
Digestion & 
Assimilation
Expenditure on 
Purchasing Domestic 
Technology 
Raw Chemical Materials 
and Chemical Products 195,478 43,023 46,610 
Medical and 
Pharmaceutical Products 35,815 34,971 56,041 
(Source) NBSC 
 
Given the limited resources in the initial development stages and their weak innovation 
capability, Chinese pharmaceutical firms have to choose a down-to-earth strategy: 
“combing imitation and innovation together, while first imitating” has become the 
representative development mode of medicines in China. Nowadays, most chemicals in 
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China are generic drugs. Only several medicines (such as Qinghaosu, etc.) are admitted 
internationally as innovative drugs. Due to insufficient R&D and the lack of 
independent intellectual property rights (IPR), Chinese medical firms have to focus on 
producing generic drugs. Dependence on generic drugs, however, leads directly to tight 
competition, which prevents firms from enter into a well-ordered developing orbit, 
further limiting the development of the Chinese pharmaceutical industry. 
 
Fortunately, we are pleased to find some promising firms (such as Kanion, Hisun, Fosun, 
DCPC, etc.) that are paying more attention to R&D and attach importance to innovation. 
The highest R&D investment ratio, which we knew through a field survey, reached 
about 12% (Kanion). The feature that all these firms have in common is that they have a 
good management infrastructure. These pioneers utilize specific APIs and R&D into 
new drugs as breakthroughs, and they benefit from differences in products, technology, 
and marketing strategies. They have already started to upgrade the Chinese 
pharmaceutical industry structure with the symbol of internationalization and 
innovation. We will discuss this type of firm in detail and introduce their developing 
experiences in case studies. 
 
5.2.2 Basic Information on R&D in Representative Chinese Pharmaceutical Firms 
In this section, we summarize the basic information on R&D in Chinese pharmaceutical 
firms that we visited between May and June 2007. 
  Investment by firm consists of physical capital and human capital. Of these two, 
innovation heavily relies on human capital. In order to invest physical capital, a firm 
must need capital. Speaking reversely, if you can finance, you can invest and acquire 
physical capital. However, human capital is something different: first, ownership of 
human capital is ambiguous. Though a manager or company pays a scientist’s salary, 
his boss can bring him to a laboratory, but cannot have him seriously engaged in 
research and development work. Secondly, innovation comes from ambiguous 
ownership, cooperation with research staff, or some type of interaction. Therefore, the 
allocation of decision-making rights related to innovation is very important in this field. 
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Table 7:  Basic R&D Information From Visited Firms (May - June 2007) 
No. Firm
Sales (2006) 
(bil. RMB) 
R&DExpenditur
e/Sales 
(%) 
Who decided which drugs should be 
listed? 
Who provided information on new drugs Notes 
1 A 2.40 10 Expert Committee R&D Department  
2 B 1.51 8 Expert Committee Market analysis, and consultation with an outside expert  
3 C 2.69 5-6 Decentralized by the size of investment Technology Center and Marketing Department  
4 D 0.20 6 - Research Institute and Information Department  
5 E 50 20 Headquarters in Japan Shanghai Corporate  
6 F 1.42 8 Directors’ meeting R&D Team, Marketing Team, Expert Committee
Practically, the 
Chairman and 
management are a part 
of the R&D team. CTO 
7 G 0.85 8-12 Chairman, Directors’ meeting R&D Team  
8 H 2.70 8-9 Expert Committee   
9 I 3.60 1.5 
Directors’ meeting or GM 
office(determined by the size of 
investment) 
(1) Laboratory, (2) New Drug Research Center  
10 J 1.00 6 Expert Committee (Management + outside experts) (1) Hospital, (2) R&D Team, (3) Sales 
Limit of expected sales 
0.5 bil / year 
11 K 0.40 8 Directors’ meeting in the company itself, not the holding company   
12 L 4.05  Chairman, Directors’ meeting at headquarters (1) Marketing and Sales, (2) R&D Team  
(Source) Author 
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5.2.3 Market, Resource Allocation, and Organization Innovations 
 
Although the achievements made by the Chinese pharmaceutical industry’s R&D is not 
so exciting, there have been some original innovations that are worth considering, 
primarily innovations in the market, resource allocation and organizational structure. 
 
According to the “Decision of the Central Committee of the Communist Party of China 
and the State Council on Implementing the Outlines of Science and Technology 
Planning and Strengthening the Capabilities in Self-Innovation”, China aims to establish 
a technical innovation system which involves “market-oriented, enterprises as the main 
body, and combing industry, universities, and institutes together to innovate”. To be 
leading players in innovation and in order to provide sufficient, affordable, and effective 
drugs, Chinese pharmaceutical firms usually adopt the following methods:  
 
1. Staying close to the market by means of strict market-oriented technical 
innovation. When market demand arises, it will be detected immediately (indeed, 
some demands are raised intentionally). The target product will be identified and 
its efficacy will be realized via a series of R&D processes and technical means, 
and be launched in the market quickly; 
2. Due to conflicts of interest and a lack of complementary activity, cooperation 
among Chinese pharmaceutical firms is infrequent. However, there is a lot of 
cooperation between Chinese pharmaceutical firms and universities and 
institutes. In addition, Chinese pharmaceutical firms recognize that there is a 
large gap in the R&D of innovative drugs, compared with advanced international 
firms. They are aware that R&D must meet international standards, and they 
look to utilize international resources for technical innovation (such as 
improving their technical capability through international cooperation), in order 
to create an internationalized means for R&D and operation management; 
3. Chinese pharmaceutical firms usually adopt a “multi-department cooperation” 
strategy for organizing R&D. Generally, R&D acts as the leading department, 
and the departments of Marketing, Finance, and Manufacturing take part in the 
project. This kind of organization innovation can efficiently accelerate the 
transfer of new products from R&D to production and then to the market. 
 
5.2.4 Innovation Achievements in the Chinese Pharmaceutical Industry 
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Although the Chinese pharmaceutical industry currently has not seen as good results 
from innovation as we might wish, there are still several noteworthy achievements that 
we would like to highlight. 
 
Above all, the Chinese pharmaceutical industry’s efforts in innovation have ensured that 
people can obtain sufficient, affordable (although people complain that “it is difficult 
and expensive to see a doctor”, they unanimously agree that “it is a problem with the 
system”) and efficient drugs. Currently, China can independently produce a series of 
products of APIs, doses, biologics, Traditional Chinese Medicines, medical treatment 
instruments, and pharmacy machines, and has already set up a whole system including 
science and research, education, production, circulation and other assisting 
establishments. 
 
Secondly, the government’s efforts and assistance have significantly influenced 
pharmaceutical innovation in China. Most of the pharmaceutical firms we visited have 
received R&D funds (some more, some less), finance aid and/or preferential tax 
treatment from local and/or central government bodies. These favorable policies and 
measures provide a great incentive for firms to pay more attention to R&D. To the best 
of our knowledge, almost all innovative drugs which have independent IPR (admitted 
internationally) came from The National Key Technologies R&D Program (NKTRDP). 
National science and technology projects have achieved remarkable results and 
advanced the Chinese pharmaceutical industry’s progress in R&D. For example, both 
Fosun’s Artesunate (which possesses the No.1 certificate for a Class One New Drug in 
China) and DCPC’s “Beijing Hypertensive No. 0”, have benefited from NKTRDP. 
National R&D projects can utilize and unite social resources and power, concentrate to 
invest in and attack some key technical problems, and also promote science and 
technology’s advancement and independent innovation in the pharmaceutical industry. 
 
Finally, some ambitious and conscientious pharmaceutical firms are growing rapidly by 
relying on R&D. Through the pursuit of profit and efficiency, these firms continuously 
improve and innovate, reducing production costs, strengthening scientific management, 
and trying any way to meet the customer’s demand. We believe that firms of this kind 
have a promising future and will see quick development, if their market exploration and 
expansion is not only limited to their home base, but also expands overseas (this 
requires internationalization talents in R&D, management, and global marketing, etc). 
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5.2.5 Development Phase and Basic Evaluation 
 
The Chinese pharmaceutical industry’s development, the degree of pharmaceutical 
patent protection and supervision of drugs, and the level of engagement in international 
affairs, all demonstrate that China is a large but not a powerful country when it comes to 
producing drugs. Most Chinese pharmaceutical firms are still relying on massive 
manufacturing, low resource costs and low labor costs to struggle and develop forward. 
The basic evaluation of the Chinese pharmaceutical industry’s innovation is as follows: 
 
1. The Chinese pharmaceutical industry is still striving in the primary stage of 
R&D. Most of its innovation takes place in the fields of technology, the market, 
resource allocation and organization. By and large, product innovation is very 
sparse and is still in the imitation-innovation stage. 
2. China is in the upstream of the global pharmaceutical industry supply chain, 
playing the role of a manufacturer and a provider of APIs and raw materials. 
3. Chinese pharmaceutical firms (especially chemical firms) mainly produce 
generic products and focus on the extremely competitive domestic market. 
 
 
5.3 Evolution and Motivation of Innovation in the Chinese 
Pharmaceutical Industry 
 
5.3.1 Major Innovation Patterns in the Pharmaceutical Industry 
 
5.3.1.1 Characteristics of R&D in new drugs: greater difficulty, longer R&D periods, 
increasing investment, less marketable innovative drugs 
 
Pharmaceutical R&D requires huge investments. In 2003, the average R&D cost of an 
innovative drug approached US$700-800 million, and only 34 innovative drugs were 
approved to enter market that year. Pharmaceutical firms need to invest at least 
US$150-200 million dollars in R&D annually in order to retain their innovative 
potential in the international market. In the US, the average time it takes for an 
innovative drug to go through all the phases, from R&D right through to being granted 
approval by the FDA to enter the market, is 12.5 years. The two most time-consuming 
phases are drug discovery (5 to 7 years) and clinical research (5 to 8 years). But 
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accompanying this huge investment and high risk, is the return of a tremendous 
monopoly on profits during the patent protection period (usually 20 years) if an 
innovative drug has been developed successfully. The detailed R&D flow of a 
innovative drug, and the values and risks associated with each phase, are set out in 
Figure 1. 
 
Figure 1:  R&D Flow of an innovative drug, and the value and risks in each phase 
Source: [1] 
 
Figure 1 shows that the highest investment point appears in clinical phases I-III. The 
large numbers of patients and the history of the illness, along with the low costs and 
other favorable clinical examination conditions, drive more and more international 
R&D organizations to carry out clinical examinations of new drugs in China. This trend 
provides an opportunity for some Chinese pharmaceutical firms that have clinical drug 
resources and a strong capability for organization. The qualified firms can utilize the 
economic rules, their own abilities, and the advantage of being close to the market, to 
cooperate with international R&D organizations first in the clinical phase, and then 
gradually expanding to other phases. 
 
5.3.1.2 Major patterns in pharmaceutical industry innovation: product and technology 
innovation 
 
All five major types of innovation patterns (product innovation, technology innovation, 
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market innovation, resource allocation innovation, and organization innovation) can be 
found in the innovation processes of pharmaceutical firms. Of these, product and 
technology innovation are the two most prominent modes. Figure 2 details the processes 
of a pharmaceutical firm’s technical innovation and the related factors within each 
period.  
 
Figure 2: Model of Pharmaceutical Firm Technology Innovation Process 
Source: [1] 
 
Usually, pharmaceutical product innovation happens mainly during the Drug Discovery, 
Pre-clinic, and Clinic phases. The innovative results include innovative drugs, 
imitation-innovative drugs, and imitation new drugs (new forms of dosage and new 
indications developed from existing drugs). 
 
Generally, innovative drugs and imitation-innovative drugs are more difficult to 
generate than imitation new drugs. On the other hand, highly-technical R&D is also 
required for high-level imitation new drugs. The development of imitation new drugs is 
characterized as integrated innovation. 
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Pharmaceutical technology innovation usually happens in the manufacturing phase by  
introducing new manufacturing technology and new methods of quality control to 
produce existing drugs. Technology innovation makes production easier by making it 
less time-consuming and less energy-consuming, while at the same time obtaining a 
better quality of product. 
 
A pharmaceutical firm’s market innovation is usually market-oriented, continuing to 
develop new markets and creating new marketing mechanisms. Resource innovation, 
meanwhile, means to optimize allocation of pharmaceutical resources in order to 
improve the efficiency of the utilization of resources by setting up a global integrated 
mechanism and channels. Generally speaking, organization innovation in 
pharmaceutical firms refers to building an innovative strategic alliance or cooperative 
R&D organization. 
 
5.3.2 Innovation Patterns in the Chinese Pharmaceutical Industry 
 
Although Chinese pharmaceutical firms’ capability for innovation is relatively weak, 
their investment in the R&D of new drugs is severely insufficient, and there are very 
few local innovative drugs, nevertheless, some representative Chinese pharmaceutical 
firms have carved out their methods of innovation with individual characteristics. We 
have summarized the most typical and impressive patterns of innovation as follows: (1) 
product innovation for R&D into new drugs; (2) technology innovation to improve 
production efficiency and capacity; (3) marketing innovation in promoting the brand 
and improving the firm’s status; (4) organization innovation to improve the efficiency of 
R&D, manufacturing, and market development. 
 
5.3.2.1  Product innovation for R&D into new drugs 
 
In this section, we introduce several shining examples of product innovation in the 
Chinese pharmaceutical industry, although they are a rarity. As we discussed earlier, 
national R&D projects played an important role in this field. 
 
Qinghaosu, a world-renowned chemical product that was independently developed by 
Chinese scientists in 1971, and its derivatives, Artesunate, which has the characteristics 
of low toxicity, swift time to effect, high effectiveness, and low recrudescence, is the 
only effective water-soluble derivative of Artemisinin and was given an award as the 
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“most effective” antimalarial drug by the WHO and was listed among the essential 
antimalarial drugs in 2000. It is also the first product to possess the First Class New 
Drug Certificate issued by China’s Ministry of Health. Favorable reviews noted that 
Artesunate had taken a pragmatic step forward in the exploitation of the international 
market as a finished product with Chinese independent IPR. 
 
 
Case Study: Fosun Pharmaceuticals -- Innovation for Good Health 
 
Fosun Pharmaceuticals (Fosun Pharma) was founded in 1994 and grew to become 
a leading pharmaceutical enterprise in China. Its businesses cover pharmacy, 
clinical diagnostic and therapeutic products. It has the largest drug retail and 
distribution network in China and is aiming at the global market. It is listed on the 
Shanghai Stock Exchange with a market capitalization of about RMB12 billion. 
 
The Anti-malaria drug Arteannuin, which was developed by Guilin 
Pharmaceuticals (a subsidiary company of Fosun Pharma), has been recommended 
by the WHO as the most preferred drug for treating malaria. This is the first 
Chinese pharmaceutical ingredient with an independent intellectual property right 
that has reached the global market. In 2005, Fosun Pharma passed the WHO's 
direct supplier qualification authentication, and became China's only direct 
supplier to the WHO to date. Arteannuin was the first drug approved and has 
obtained the No.1 Certificate of the First Class New Drug in 1987. The form of 
Arteannuin for injection possesses the No.2 Certificate. 
 
Fosun Pharma actively encourages product innovation, and allocates 5-7% of its 
annual revenue to innovation, especially R&D. Fosun Pharma has established an 
R&D innovation team lead by world-class scientists, who have established 
platforms for the world's leading technologies such as dry powder precision nasal 
spray, gradual controlled release, liposome, etc. By December 31st, 2006, Fosun 
Pharma had obtained a total of 54 patents, with 184 still in the application process. 
In the treatment of malaria, diabetes, hepatic diseases, and gynecological diseases, 
Fosun Pharma has developed leading products such as Arteannuin, Insulin, 
Huahong tablets, and Atomolan. Fosun Pharma's production lines for major active 
pharmaceutical ingredients and some drugs have passed American, EU, WHO and 
GMP authentications. The company has received the necessary eligibility for 
entering the international mainstream markets. 
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Strengths: 
• Leading products in various market segments: Arteannuin, Insulin, Huahong 
tablets, Atomolan. 
• Strong research and development platform:  
1. R&D team: a national-grade technical center with over 500 researchers, 
including experts in the pharmaceutical industry with R&D experience in 
world-class pharmaceutical enterprises and GMP experiences. 
2. Products: currently, there are around 200 medicines in various stages of 
development, with more than 10 being included in key clinical research 
projects scheduled for 2007. The new products cover treatments for 
malaria, diabetes, gynecological diseases and hepatic diseases. 
3. Patents: 54 patents have been acquired and 184 are still in the application 
stage. 
• China's largest Medicine Distribution and Retailing Network 
• Strength in scalability and M&A capabilities: achieved rapid growth in 
revenue and expansion through M&A. 
Strategies: 
1. Discover, cultivate and develop heavyweight products. 
2. Establish the largest pharmaceutical retail and distribution network in 
China. 
3. Actively explore opportunities in the overseas markets, increasing the 
awareness and recognition of Fosun's brand among international 
audiences. 
4. Actively seek opportunities for M&A, and expand the business scale. 
 
Discovery of Qinghaosu 
 
Qinghaosu (ARTEMISININ) was originally developed in 1971 in China (the 
Chinese Institute of Material Medicine) from the plant Artemisia annua L (sweet 
wormwood), and it is the active ingredient in Qinghao, a Chinese herbal tea that 
has been used for over 1000 years to treat malaria and haemorrhoids. Project 
“523” (the Chinese antimalarial drugs cooperation research, a project cooperated 
on at a national level) for developing new antimalarial drugs was established in 
1969. By analyzing traditional prescriptions, the research group screened over 200
herbs and 380 abstracts from them by using the malarial models of mice or 
monkeys. 
 Enlightened by the classical remedy “immerse a handful of Qinghao in two liters 
of water, get the juice and drink it” (Ge Hong: The Handbook of Prescriptions for 
Emergencies, circa. 340 AD, Eastern Jin Dynasty), researchers studied the 
antimalarial effect of Qinghao. The treatment was understood when temperature, 
enzymolysis, solvents, species, portions and the season for collecting the herb 
were systematically considered. A new antimalarial drug was developed in 1971, 
illustrating the scientific picture of Qinghaos antimalarial nature for more than 
1000 years. The new compound isolated from Artemisia annua L. is entitled 
Qinghaosu. 
 
Sources: 
(1) Interview with the Mangers of Fosun Pharma in December 2006, May and June
2007, respectively.   
(2) http://www.fosun.com.cn 
5.3.2.2 Technology innovation to improve production efficiency and capacity 
 
Innovations are not only inventions but also adoptions. They come in many types and 
vary greatly in complexity and scope. Companies attempting to make a profit cannot 
continue to operate for long periods without innovating. It is also an without doubt that 
different companies take different approaches to the use of innovation in an attempt to 
improve their performance, depending on the company’s strengths and weaknesses, and 
the opportunities and threats presented by the firm's environment. 
 
In the Chinese pharmaceutical industry, “Technology Introduction - Digestion & 
Assimilation - Re-innovation” is a prevalent pattern of innovation. Within this pattern, 
technology innovation as a means to improve production efficiency and capacity is 
frequently observed. For example, DCPC invested more than RMB338 million between 
1978 and 1997 to implement technology reconstruction and introduction, which in turn 
helped it take the lead over its competitors in production capacity, technical equipment 
and its manufacturing environment. Furthermore, DCPC set up 3 joint-venture 
pharmaceutical firms between 1992 and 1994 in order to introduce overseas equipment, 
technologies, and patent products, which greatly improved the standards of its 
manufacturing technology and quality management. Through all these tactics, DCPC 
successfully improved its products’ technology, quality, production capacity, and sales. 
By means of technology reconstruction and improvement, in particular focusing on 
technology innovation and re-innovation after technology introduction, DCPC smoothly 
 106
promoted its technology reconstruction and upgrades. For instance, DCPC 
independently invented the “Two- step VC Fermentation” technology, which was 
awarded the 2nd Prize for National Inventions in 1983. 
 
Technology introduction is one efficient and important approach to narrowing the 
technology gap between developed countries and developing countries. If Chinese 
pharmaceutical firms can successfully assimilate and then exert more efforts in 
switching from technology introduction to technological innovation, then perhaps they 
can explore the evolution process of re-innovation and enjoy the advantage of a late 
move from imitation to innovation. Within this process, contributing the accumulated 
input of R&D to the imitative innovation project may be of significance. Continual 
R&D input should be the key to triggering a situation where the “second mover” has an 
advantage over those who moved first. 
 
5.3.2.3 Marketing innovation in promoting the brand and improving the firm’s status 
 
Being market-oriented is perhaps one of the most essential keys to an organization’s 
success in highly competitive and rapidly changing markets and technology 
environments. This requires the integration of innovation with the corporate 
development strategy, to ensure that R&D works effectively with other functions - like 
marketing - to generate new innovations that are relevant to customer. 
 
Pharmaceuticals rely heavily on their marketing policy, but the marketing strategy 
greatly affects pharmaceuticals as well. Pharmaceutical firms need to spend large 
amounts on advertisements and other forms of marketing (1) for the purpose of brand 
cultivation, product perception, and to raise the customer group; and (2) to drive bad 
pharmaceuticals and un-qualified firms out of the competition. 
 
Many new and innovative products that have great potential fail, not because of 
technical problems, but due to the lack of an innovative business model. A notable 
phenomenon in the Chinese pharmaceutical industry is that another focus of firms is on 
marketing innovation. The major activities in this field include: 
 
1. Close cooperation with hospitals in order to serve consumers better; paying 
more attention to clinical distribution and knowledge-marketing to increase the 
consumer group; 
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2. Marketing innovation by means of applying E-business technologies to 
the enterprise’s logistics and marketing systems; 
3. Efforts to develop international and other diverse subdivision markets. 
 
5.3.2.4 Organization innovation to improve the efficiency of R&D, manufacturing, and 
market development 
 
The organizational form of technological innovation activities in pharmaceutical 
industry has a wide scope, and there are different points-of-view in both academia and 
the industry. Usually, Chinese pharmaceutical firms’ organization innovation method is 
to build a strategic innovation alliance or cooperative R&D organization, and to 
emphasize the importance of internal multi-department cooperation. 
 
(1) Joint innovation with external partners to build strategic networks of 
technological innovation. The main objective of this kind of organization form is to 
utilize the complementary core-competences of different firms to maximize the 
benefit of their cooperation. Frequently-observed joint-innovation organization 
forms in the Chinese pharmaceutical industry are summarized as follows: 
• Industry, University, and Institutional players cooperate to innovate; 
• Horizontal cooperation with international giants; 
• Vertical cooperation with hospitals and other organizations in the value chain.  
 
(2) Internal cooperation and mutual support among the R&D, Manufacturing and 
Marketing departments. Generally, the R&D department acts as the project 
development’s “engine” while the Marketing, Finance, and Manufacturing 
departments also participate in the project’s development. Since the Marketing and 
Manufacturing departments take part in the project during the early stage of R&D, 
the marketing people have a deeper understanding of the project’s indications and 
clinical application, while the Manufacturing department can prepare itself properly 
for any technology and equipment requirements, and for quality control. Feedback 
and suggestions from these departments also helps the R&D department to improve 
its own work. This kind of innovative organization form, which combines 
manufacturing technology and quality management, adequately utilizes the 
advantages of market development and extension, and it can certainly efficiently 
speed up the transition to production and the new products subsequently being 
introduced to market successfully. 
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5.3.3 The Evolution of Innovation in the Chinese Pharmaceutical Industry 
 
By considering the characteristics of pharmaceutical technical innovation and its flow, 
and integrating this with the current status of Chinese pharmaceutical R&D, we would 
like to give a brief introduction to the evolution of innovation in the Chinese 
pharmaceutical industry. 
 
Table 8: Evolution of Innovation in the Chinese Pharmaceutical Industry 
 
Stage Representative Product & Technology, and Milestone
Independent R&D and Deferred 
Imitation 
(~1978) 
Insulin Synthesis  
Qinghaosu 
Sodium Dimercaptosuccinate  
Technology Introduction and 
Reformative Innovation 
(1978～1990s) 
“Two- step VC Fermentation” Technology 
Digestion, Assimilation & 
Re-innovation 
(1980s～1990s) 
Industrialization Projects of Series of Vitamins 
Technology innovation in Dexamethasone 
Interferon Spray 
Imitation-Innovation 
(Mid 1980s~Present) 
Various “me-too” drugs 
Independent Innovation 
(Late 1990s ~ ) 
Polydatin Injection  
Tongxinluo Capsules Containing Attritive Powder 
Guizhi Fuling Capsule 
Shen Yi Capsule 
Source: Author  
 
Prior to the reforms in China, Chinese researchers practiced R&D independently and 
achieve several important results, such as the synthesis of Insulin and the discovery of 
Qinghaosu. During this period of self-sufficiency, China’s pharmaceutical industry 
produced a series of basic drugs, which were usually older generic products, for the 
people’s healthcare. 
 
During the stage of “Technology Introduction and Reformative Innovation (1978～
1990s)”, Chinese pharmaceutical firms focused on upgrading their production facilities 
 109
and capacity, reconstructing and improving the technology flow by introducing new 
technologies and learning from leading international companies. 
 
During the stage of “Digestion, Assimilation & Re-innovation (1980s～1990s)”, most 
Chinese pharmaceutical firms carried out a great deal of development research and, 
after digestion, assimilated the key elements after introducing overseas patented 
technology. This activity greatly improved their technical capability. 
 
At the stage of “Imitation-Innovation (Mid 1980s~Present)”, Chinese pharmaceutical 
firms are now able to provide abundant drugs for people’s healthcare, although most of 
them are generic drugs. Some pioneers, however, have started to pay more attention to 
independent R&D and are try to provide innovative products. 
 
Since the late 1990s, in keeping with the national “independent innovation” 
development policy, more and more Chinese pharmaceutical firms are attaching 
increased importance to innovation, and some innovative firms and their own 
innovative products are starting to emerge. 
 
5.3.4 The Chinese Pharmaceutical Industry’s Experiences and Issues 
 
The innovation of the pharmaceutical industry requires that enterprises be vast enough 
to bear the weight of increasing R&D costs and the huge risks involved. If they are not 
able to, then they need either a mechanism to share the risks or a suitable form of 
organization for their R&D. 
 
We would summarize some of the experiences the Chinese pharmaceutical industry has 
seen during its development as follows: (1) gradually developing in a proper sequence 
based on self-competence. For example, a process of gradual accumulation from 
imitative innovation to integrated innovation, cooperative innovation, and finally 
independent innovation, according to the enterprise’s strength; (2) the rapid 
development of the domestic market has provided a favorable space for Chinese 
pharmaceutical firms to grow; (3) the vision, force and leadership of ambitious 
entrepreneurs. 
 
Analysis of Chinese pharmaceutical industry’s development also suggests that, in order 
to guarantee rapid development, we need to enhance competence in the following areas: 
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(1) an effective and flexible strategy of pharmaceutical intellectual property protection; 
(2) a powerful national R&D organization infrastructure. (As we discussed in Section 
5.2.4, National Science and Technology projects and other public sector R&D programs 
play an important role in the development of the Chinese pharmaceutical industry); (3) 
an integrated innovative system that consists of large-scale enterprises with independent 
innovation capabilities. 
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Case Study: Hisun Pharmaceutical -- Innovation Theory of “Fish” 
 
Zhejiang Hisun Pharmaceutical Co., Ltd. was established in 1956 and has evolved into one of 
the largest bulk Active Pharmaceutical Ingredient (API) manufacturers in China. Hisun ranks 
among the top 20 Pharmaceutical companies in China as well as in the top 500 Chinese 
companies overall. 
 
The Group's principal activities are developing, manufacturing and selling chemical raw 
material medicines, chemical intermediaries, medicinal preparations, biological medicines, 
Chinese patent medicines and medicine auxiliaries. Other activities include researching and 
producing necessary raw materials and importing machinery and equipment, apparatus and 
spare parts. The Group has distribution networks not only in China but also in the United 
States, Germany, Austria, Belgium and the United Kingdom. Its products are available in 
more than 30 countries and regions around the world.  
 
Hisun exports 80% of API production to North America, Europe, South America, and Asia. 
Hisun has had 9 successful FDA field inspections since 1992. Currently, Hisun has 15 FDA 
product approvals, 11 EDQM (CoS) approvals, and 73 products registered throughout the 
major pharmaceutical markets worldwide. 
 
Hisun’s new state-of-the-art Pharmaceutical Research Institute was established in 2001. It 
focuses on improving the core competency of producing cGMP quality active pharmaceutical 
ingredients through organic synthesis and fermentation. Depending on this institute, Hisun 
will develop new R & D projects, including biologicals, and joint R & D projects and contract 
research with multinational pharmaceutical companies. 
 
Hisun’s technical strength includes Fermentation and Organic Synthesis. Hisun is one the 
largest Chinese producers of Anti-Infectives, Oncologicals, Cardiovascular, and Animal 
Health Drugs. In addition, Hisun is producing finished dosage products, including tablets, 
capsules, and injectables. 
 
Hisun has invested over 10 million USD over the past five years in plant renovation and new 
construction. Key process parameters are computer controlled. Hisun utilizes various drying 
technologies in its production including lyophilization, rotary drying, spray drying, filter 
drying, and conical mixing drying. In addition, Hisun filtration technologies include press 
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filtration, cermanic membrane filtration, reverse osmosis, nanofiltration, and ultra filtration. 
Hisun has established long-term relationships with more than 20 world class Chinese research 
institutes. These relationships provide Hisun with an additional source of R & D projects for 
new and existing molecules as well as Traditional Chinese Medicine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Innovation Theory of “Fish” of Hisun Pharmaceutical 
 
Sources: (1) Interview with Mangers of Hisun in November 2006 and June 2007, respectively. 
(2) http://www.hisun.com.cn 
“Build a Pond to Raise Fish” 
Independent Innovation 
“Fill with Water to Raise Fish” 
Ally to Attack Key Problems
 “Borrow a Pond to Raise Fish” 
Cooperate to Develop 
 “Buy Fish” 
Purchasing Production 
 
 
5.5 Summary 
 
We can summarize our observations of the Chinese pharmaceutical industry in this 
section as follows: 
 
(1) Under the constraints of limited resources and infirm innovative capabilities, it is a 
feasible choice for Chinese pharmaceutical firms to adopt a policy of 
imitation-innovation during the current stage. For those firms that have been qualified in 
GMP, and have both a solid technical foundation and some R&D capability, if they can 
learn from the successes and failures of leading innovators and improve on this basic 
tenet – to invest their main resources in the middle and later stages of innovation, such 
as in the fields of technology design, quality control, cost control, production 
management, and marketing, in order to produce more competitive products with better 
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performance, higher quality, and lower price - it is quite possible for them to take the 
advantage in competition. Once these firms have won dominance in their competition, 
then they can pursue further development while continuing to grow, taking care of both 
their short-term objectives and their long-term vision and strategy. Thus they can aim at 
improving their independent innovative capability via imitation, in order to achieve the 
ultimate goal of Innovation in development and growth. 
 
(2) The lack of talents in every field (R&D, Management, and Marketing) is another 
problem facing the Chinese pharmaceutical industry, and we believe it is the key factor 
limiting the industry’s development. The Chinese educational system must be aware of 
this factor and must try its best to attract more talents to work in the pharmaceutical 
industry. This may lead to a permanent cure, helping the Chinese pharmaceutical 
industry to transition from imitation-innovation to independent innovation.  
 
(3) An effective patent protection system should developed in phase with international 
regulations to promote Chinese pharmaceutical firms’ innovative capabilities. On the 
other hand, it should also reflect the reality of the Chinese pharmaceutical industry’s 
development. A patent protection strategy that brings “gradual progress in the proper 
sequence” and “accords with the current stage of national development”, may be more 
suitable for the development of the Chinese pharmaceutical industry. 
 
(4) National innovation-encouragement policies have begun to have a positive effect on 
the Chinese pharmaceutical industry. The State Development Reform Committee 
(SDRC) has established “Guidance for the Eleventh Five-Year Development Plan of the 
Pharmaceutical Industry”, which emphasizes that the government will increase its 
support of R&D projects in the pharmaceutical industry and will work to realize the 
industry’s industrialization through effective taxation and financial measures, and so on. 
Together with other supporting policies and detailed rules, we believe that the 
innovation capacity of enterprises will improve significantly in the coming years. 
 
To better understand how that Chinese pharmaceutical industry did in terms of 
innovation and how it will develop over time, several un-discussed issues require 
further study in detail: 
 
1. Detailed analysis of the development background (market and system 
environment) of the Chinese pharmaceutical industry; 
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2. Detailed analysis, evaluation and forecast of development trends in the Chinese 
pharmaceutical industry; 
3. Comparison study of the development of the Indian pharmaceutical industry; 
and also the development experiences and lessons of other international pioneers 
in the pharmaceutical industry. 
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